Analysis revealed anti-PD-L1 treatment with or without chemotherapy in KRAS mutant NSCLC sufferers to exhibit an enhanced OS (0.59) and PFS (0.58), compared to singular chemotherapy, in both clinical trials. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.